decitabine + rituximab + gemcitabine + cisplatin + dexamethasone

This is a multi-agent chemotherapy regimen combining five drugs with distinct mechanisms of action, primarily used as a salvage therapy for relapsed or refractory aggressive B-cell lymphomas such as diffuse large B-cell lymphoma (DLBCL) and other non-Hodgkin lymphomas. - **Decitabine** is a pyrimidine nucleoside analogue that inhibits DNA methyltransferases, leading to hypomethylation of DNA and reactivation of tumor suppressor genes[6][1]. - **Rituximab** is a monoclonal antibody targeting CD20 on B cells, resulting in cell lysis through immune-mediated mechanisms[3][2]. - **Gemcitabine** is an antimetabolite that inhibits DNA synthesis by incorporating into DNA strands during replication[3][4]. - **Cisplatin** forms crosslinks in DNA, causing apoptosis by interfering with replication and transcription[3][4]. - **Dexamethasone** is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects. The combination aims to maximize cytotoxicity against malignant lymphocytes while providing synergistic effects between agents. The regimen has been shown to be effective as salvage therapy prior to autologous stem cell transplantation in patients who have failed previous lines of treatment for aggressive lymphoma[2][5][1].

Other names

RGDP-Cisplatin-Dexamethasone-Gemcitabine-RituximabR-GDPGDP plus rituximab plus decitabine